HCA Florida Capital Hospital announces new chair, vice chair of Board of Trustees
HCA Florida Capital Hospital announced in March the appointment of Edwin H. Moore, Ph.D., as chair of its board of trustees and Niraj Pandit, MD, as vice chair.
'We are honored to have Ed Moore and Niraj Pandit lead our board of trustees,' said Tavarres Jefferson, chief operations officer at HCA Florida Capital Hospital. 'Their deep commitment to public service, leadership experience and dedication to the community will be invaluable in advancing our hospital's commitment to the care and improvement of human life.'
Moore has served on HCA Florida Capital Hospital's board of trustees since 2019. He is the former president of the Independent Colleges and Universities of Florida, a Tallahassee-based association of 31 private, not for profit colleges and universities. Moore retired as President Emeritus in 2019 after a 16-year career with ICUF. He also served as the executive director of the Higher Education Facilities Finance Authority in Florida and as chief executive officer of the Florida Independent College Fund, a non-profit organization.
Pandit has also served on the HCA Florida Capital Hospital Board of Trustees since 2019 and is a board-certified interventional cardiologist with HCA Florida Healthcare. He earned his medical degree and completed his internship and residency in internal medicine from the Medical College of Pennsylvania and Hospital. He went on to complete his cardiology fellowship at Cooper University Hospital in New Jersey. Dr. Pandit is board-certified in internal medicine, cardiovascular diseases and interventional cardiology.
This article originally appeared on Tallahassee Democrat: HCA Florida Capital Hospital announces new chair, vice chair
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
11 minutes ago
- CNBC
Nasdaq-traded Chinese herb company hits near $30 billion market value after speculative surge
Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience company with no revenue, is the latest speculative overseas stock to attract an unusual surge in trading demand. Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivity disorder and autism, more than tripled on Monday — soaring more than 280% by the close. A 38-for-1 split declared on June 2 took effect on Monday. The company's year to date performance is off the charts too, having risen 46,000% in 2025. By Monday's close, Regencell, founded in 2014 and traded on Nasdaq under the ticker 'RGC' since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ. Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data. Regencell is the latest example of a speculative international stock attracting attention during summer trading. In August, 2022, for example, AMTD Digital, a Hong Kong-based fintech company, climbed 126%, briefly giving it a market value greater than Coca-Cola and Bank of America. Regencell's market value is now about equal with Nasdaq-traded Lululemon and tops Super Micro Computer and Fifth Third Bancorp. Earlier this month, Regencell explained the stock split as designed solely "to enhance liquidity in the market for the company's ordinary shares and make the shares more accessible to investors." Stock splits do not change anything fundamentally about a company. Regencell's surge also came amid an increased focus on alternative medicines after Robert F. Kennedy Jr. was sworn in as Secretary of the U.S. Department of Health and Human Services in February. Kennedy, a vaccine skeptic, has taken steps to discourage routine immunizations in the U.S., last week removing all of the members of a panel that advises the Centers for Disease Control and Prevention on vaccines. Regencell's stock often makes huge one-day swings. For example, shares jumped roughly 30% on March 21, before dropping 30% the following trading day. In spite of the wild spike in the stock, little is known about the efficacy and commercialization of the Regencell's treatments for ADHD and Autistic Spectrum Disorders. Regencell's business centers on a proprietary Traditional Chinese Medicine formula (TCM) developed in a partnership with TCM practitioner Sik-Kee Au using his "Sik-Kee Au TCM Brain Theory." Sik-Kee Au is the father of the Regencell chief executive officer Yat-Gai Au, the company said in a 2022 statement. Three liquid-based, orally TCM formulae candidates claim to address mild, moderate and severe conditions and only contain natural ingredients such as so-called "detoxication herbs," blood circulation herbs and digestion herbs. "These TCM formulae form the basis of our TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD," Regencell's website reads. In its latest annual report filed last October, Regencell said that it had not generated any revenue, nor filed for any regulatory approvals of its TCM formulas. For the fiscal years ended June 2024 and 2023, Regencell incurred total net losses of $4.36 million and $6.06 million, respectively, according to a 20F filing to the SEC. "We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," read the filing. Regencell has not responded to a CNBC request for comment. Regencell's latest patient case study, dated Nov. 15, 2023, said 28 patients were given the treatment over a period of three months in a second efficacy trial and showed an improvement in symptoms of ADHD and ASD, according to the company's webpage. In an earlier case, Regencell said in a 2021 news release that it treated a dozen patients with suspected or confirmed Covid-19 cases, using a modified version of Au's modified proprietary cold and flu TCM formula. What was described as an improvement of Covid conditions led Regencell to form a joint venture with Honor Epic Enterprises Limited in Sept. 2021 to conduct further tests and commercialize the company's Covid treatment in ASEAN countries, according to the statement. The stock has attracted little chatter on social media over the past few years. Those comments that have been made suggest both retail trader enthusiasm — and skepticism. One user on the Reddit page "r/Shortsqueeze" wrote on Monday that Regencell is "trading like a meme coin. Bought a little to see what happens and it dropped 50% right after lol." Another user said in a post made three months ago, "I scalp RGC everyday for a bit of profit." The stock jumped 1,360% in May alone. On LinkedIn in May, one investor said he "can't stop laughing," after reading the company description. Another post from a user in the pharmaceutical industry, according to his profile, last week said Regencell has become the "stock to watch" after its spike in May on "no official news or catalysts." Another LinkedIn user last month commented on Regencell, saying, "China based, low volume and no official news, bizarro." On X, one user wrote in a Monday post said, "for #CompleteBullsh__CompanyOfTheYear I nominate regencell."
Atlantic
25 minutes ago
- Atlantic
How Ivermectin Became Right-Wing Aspirin
Remember ivermectin? The animal-deworming medication was used so avidly as an off-label COVID treatment during the pandemic that some feed stores ended up going out of stock. (MUST SHOW A PIC OF YOU AND YOUR HORSE, a sign at one demanded of would-be customers in 2021.) If you haven't heard about it since, then you've existed blissfully outside the gyre of misinformation and conspiracies that have come to define the MAGA world's outlook on medicine. In the past few years, ivermectin's popularity has only grown, and the drug has become a go-to treatment for almost any ailment whatsoever. Once a suspect COVID cure, now a right-wing aspirin. In fact, ivermectin never really worked for treating SARS-CoV-2 infections. Many of the initial studies that hinted at a benefit turned out to be flawed and unreliable. By 2023, a series of clinical trials had already proved beyond a doubt that ivermectin won't reduce COVID symptoms or mortality. But these findings mattered little to its fans, who saw the drug as having earned the status of dissident antiviral —a treatment that they believed had been suppressed by the medical establishment. And if ivermectin was good enough to be rejected by mainstream doctors as a cure for COVID, health-care skeptics seemed to reason, then surely it must have a host of other uses too. As a physician who diagnoses cancer, I have come across this line of thinking in my patients, and found that some were using ivermectin to treat their life-threatening tumors. Nicholas Hornstein, a medical oncologist in New York City, told me that he's had the same experience: About one in 20 of his patients ask about the drug, he said. He remembers one woman who came into his office with a tumor that was visibly protruding from her abdomen, having swapped her chemotherapy for some ivermectin that she'd picked up at a veterinary-supply store. 'It's going to work any day now,' he says she told him when he tried to intervene. The idea that ivermectin could be a cancer-fighting agent does have some modest basis in reality: Preliminary studies have suggested that antiparasitic medications might inhibit tumor growth, and at least one ongoing clinical trial is evaluating ivermectin's role as an adjunct to cancer treatment. That study has enrolled only nine patients, however, and the results so far show that just one patient's tumor actually shrank, according to a recent scientific abstract. But these meager grounds for hope now support a towering pile of expectations. Cancer is just one of many illnesses that ivermectin is supposed to heal. According to All Family Pharmacy, a Florida-based company that promotes the compound to fans of Donald Trump Jr., Dan Bongino, Matt Gaetz, and Laura Ingraham on their podcasts and shows, the drug has 'anti-inflammatory properties that could help keep the immune system balanced in fighting infection.' (The company did not respond to a request for comment.) In sprawling Facebook groups devoted to ivermectin's healing powers, the claims are more extreme: The drug can combat a long list of conditions, members say, including Alzheimer's disease, heart disease, diabetes, autism, carpal tunnel syndrome, crow's feet, brain fog, and bee stings. As a medication that supposedly was censored by elites—if not canceled outright by woke medicine and Big Pharma—ivermectin has become a symbol of medical freedom. It's also a MAGA shibboleth: Republican-leaning parts of the country helped drive an astounding 964 percent increase in prescriptions for the drug early in the pandemic, and GOP members of Congress have used their official posts to advocate for its benefits. Ivermectin can now be purchased without a prescription in Arkansas and Idaho, and other states are considering similar measures. Health and Human Services Secretary Robert F. Kennedy Jr. has been a particularly strong proponent. In his 2021 book about the pandemic, Kennedy referred to the 'massive and overwhelming evidence' in ivermectin's favor, and invoked its 'staggering, life-saving efficacy.' He also argued at great length that the pharmaceutical industry—with the support of Anthony Fauci and Bill Gates—had engaged in a historic crime by attempting to discourage its use. Jay Bhattacharya, the director of the National Institutes of Health, has similarly backed the conspiracy theory that the use of ivermectin was dismissed by 'the powers that be' in an apparent ploy to ease the approval of COVID vaccines. (Not everyone in the current administration is a fan: Before he became the FDA's vaccine czar, the oncologist Vinay Prasad publicly disputed Kennedy's views on ivermectin, and earlier this year he called its use for cancer 'the right's version of masking on the airplane and praying to Lord Fauci.') In response to questions about Kennedy's and Bhattacharya's current views on ivermectin, the HHS press secretary Emily Hilliard told me that they 'continue to follow the latest scientific research regarding therapeutic options for COVID-19 and other illnesses.' She did not respond to questions about Prasad. The idea of using antiparasitic drugs as cancer treatments was already taking hold by the late 2010s, Skyler Johnson, a Utah radiation oncologist who studies medical misinformation, told me. In January 2017, a man with lung cancer named Joe Tippens started on a dewormer called fenbendazole, which had been suggested to him by a veterinarian. Daniel Lemoi, who had Lyme disease, had started taking ivermectin in 2012 after reading a paper on the genetic similarities between humans and horses. Tippens would go on to achieve global fame among desperate cancer patients, and Lemoi became an ivermectin influencer during the pandemic. Since then, a gaggle of dubious doctors has worked to bolster the credibility of deworming drugs within alternative medicine and anti-vaccine circles. Their underlying pitch has become familiar in the past few years: Health experts can't be trusted; the pharmaceutical industry is suppressing cheap cures; and patients deserve the liberty to choose their own medical interventions. For the rest of the medical establishment, the worldview this entails is straining doctor-patient relationships. Johnson told me that many of his patients are now skeptical of his advice, if not openly combative. One cancer patient accused Johnson of bias when he failed to recommend ivermectin. The drug is so cheap and effective, this patient had concluded, that Johnson would be out of a job if everyone knew about it. (Johnson told me that he offers patients 'the best possible treatment, no matter the financial incentive.') Ivermectin has become a big business in its own right. Online pharmacies and wellness shops are cashing in on the deworming craze, with one offering parasite cleanses for $200 a month. Meanwhile, fringe doctors can charge patients who have cancer and other diseases thousands of dollars to prescribe such treatments. Johnson's own experience suggests that the cult of ivermectin is growing larger. He told me that he's seen his patients' interest in the drug explode since January, when the actor Mel Gibson went on Joe Rogan's podcast and claimed that three of his friends had beat back their advanced tumors with ivermectin and fenbendazole, among various other potions. 'This stuff works, man,' Gibson said. Meanwhile, in the ivermectin Facebook groups—including one with close to 300,000 members—the public can read posts from a woman with breast cancer considering using ivermectin in lieu of hormone treatments; a leukemia patient who has given up on chemotherapy to ' see what happens ' with antiparasitic drugs; or a concerned aunt wondering if the drugs might help her little niece with Stage 4 cancer. But ivermectin advocacy is most disturbing in its totalizing form, wherein parasites—which is to say, the pathogens against which the drug truly is effective—are reimagined as the secret cause of many other unrelated problems. In the Facebook groups, members will share images of what they say are worms that have been expelled from their bodies by treatment. (This phenomenon brings to mind a different disease entirely: delusional parasitosis.) One recent post from the daughter of a Stage 4 lung-cancer patient showed a bloody glob that had 'dropped down into her mouth.' Commenters debated whether this might be a worm or something else. 'Blood clot from Covid vax?' one suggested. A few days later, the daughter gave an update: Her mom had gone to see the doctor, who informed her that she'd likely coughed up a piece of her own lung. The whole exchange provides a sad illustration of this delirious and desperate time. Before it turned into a conservative cure-all, ivermectin was legitimately a wonder drug for the poorest people on Earth. Since its discovery in 1973, it has become a leading weapon in the fight against horrific infections such as river blindness and elephantiasis. Yet now that substantial success seems to have given birth to a self-destructive fantasy. A decade ago, the co-discoverers of ivermectin—William Campbell and Satoshi Ōmura—were awarded a Nobel Prize in recognition of their contribution to reducing human suffering. In his formal lecture to the Academy, Campbell offered some reflections on the simple science that gave rise to the treatment, and to its wide array of applications. But his speech contained a warning, too, that any medicine that works so broadly and so well runs the risk of being handed out too often. The more benefits that such a drug provides, he told the audience in Stockholm, 'the more we must guard against the hazards of indiscriminate use.'
Yahoo
an hour ago
- Yahoo
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. Verve's lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health. The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH), a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease (CAD). VERVE-102 is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration. "VERVE-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. "Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space." "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. "In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic. Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly. Lilly shares our vision, and we believe their global research, clinical, regulatory and commercial capabilities will help to accelerate the development of our medicines. My deepest thanks to the entire Verve team for their expertise, creativity, and grit. We are grateful to the investigators and patients who have contributed to the success of our clinical trials so far. Under Lilly's stewardship, we are excited to realize the next chapter in cardiovascular care where a single treatment can lead to lifelong reduction of cardiovascular risk factors and make life better for millions of patients living with cardiovascular disease." Under the terms of the agreement, Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion). CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR. There can be no assurance that any payments will be made with respect to the CVR. The transaction is not subject to any financing condition and is expected to close in the third quarter of 2025, subject to customary closing conditions, including the tender of a majority of the outstanding shares of Verve's common stock. Following the successful closing of the tender offer, Lilly will acquire any shares of Verve that are not tendered in the tender offer through a second step merger at the same consideration as paid in the tender offer. The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve's common stock ended on June 16, 2025, the last trading day before the announcement of the transaction. Verve's board of directors unanimously recommends that Verve's stockholders tender their shares in the tender offer. To demonstrate their commitment to the transaction, Sekar Kathiresan, Andrew Ashe and entities affiliated with GV have signed tender and support agreements whereby they agreed, subject to certain terms and conditions, to tender their shares in the tender offer. The shares subject to the agreements that are beneficially owned by such stockholders represent a total of approximately 17.8% of Verve's outstanding common stock. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance. For Lilly, Kirkland & Ellis LLP is acting as legal counsel. For Verve, Centerview Partners LLC and Guggenheim Securities, LLC are acting as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP, is acting as legal counsel. About Verve TherapeuticsVerve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's proposed acquisition of Verve, regarding prospective benefits of the proposed acquisition and Verve's gene editing programs for cardiovascular disease, regarding potential contingent consideration amounts and terms, regarding the anticipated occurrence, manner and timing of the proposed tender offer and the closing of the proposed acquisition, regarding Verve's product candidates and ongoing clinical and preclinical development, regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines, and regarding the accounting treatment of the potential acquisition under GAAP and its potential impact on Lilly's financial results and financial guidance. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to consummating the proposed acquisition and any competing offers or acquisition proposals for Verve, drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the potential acquisition and its potential impact on its financial results and financial guidance, uncertainties as to how many of Verve's stockholders will tender their stock in the tender offer, the effects of the proposed acquisition (or the announcement thereof) on Verve's stock price, relationships with key third parties or governmental entities, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, transaction costs, risks that the proposed acquisition disrupts current plans and operations or adversely affects employee retention, potentially diverting management's attention from Verve's ongoing business operations, changes in Verve's business during the period between announcement and closing of the proposed acquisition, and any legal proceedings that may be instituted related to the proposed acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that the proposed acquisition will be completed in the anticipated timeframe or at all, that the conditions required to complete the proposed acquisition will be met, that any event, change or other circumstance that could give rise to the termination of the Merger Agreement will not occur, that Lilly will realize the expected benefits of the proposed acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the proposed acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's and Verve's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, neither Lilly nor Verve undertakes any duty to update forward-looking statements to reflect events after the date of this filing. Additional Information about the Acquisition and Where to Find ItThe tender offer for all of the outstanding shares of Verve described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of Verve will only be made pursuant to the tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and Verve will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF VERVE ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF VERVE SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of Verve at no expense to them at Lilly's website at and (once they become available) will be mailed to the stockholders of Verve free of charge. The information contained in, or that can be accessed through, Lilly's website is not a part of, or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC's website at In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and Verve file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly and Verve with the SEC for free on the SEC's website at Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)Ashlea Kosikowski; ashlea@ (Verve) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
